Bcl‐2‐negative <i>IGH‐BCL2</i> translocation‐negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl‐2‐positive <i>IGH‐BCL2</i> translocation‐positive follicular lymphoma
Bcl‐2‐negative <i>IGH‐BCL2</i> translocation‐negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl‐2‐positive <i>IGH‐BCL2</i> translocation‐positive follicular lymphoma
复制标题
Bcl-2 阴性 <i>IGH-BCL2</i> 易位阴性甲状腺滤泡性淋巴瘤在遗传和表观遗传学上与 Bcl-2 阳性 <i>IGH-BCL2</i> 易位阳性滤泡性淋巴瘤不同
DOI：
10.1111/his.14378
复制
发表时间：
2021
期刊：
影响因子：
6.4
通讯作者：
Nakatsuka Shin‐ichi
中科院分区：
文献类型：
--
作者：
Hamamoto Yuichiro;Kukita Yoji;Kitamura Masanori;Kurashige Masako;Masaie Hiroaki;Fuji Shigeo;Ishikawa Jun;Honma Keiichiro;Wakasa Tomoko;Hanamoto Hitoshi;Hirokawa Mitsuyoshi;Suzuki Ayana;Morii Eiichi;Nakatsuka Shin‐ichi
滤泡性淋巴瘤（FL）是原发性甲状腺淋巴瘤的一个小亚群，根据Bcl-2表达和IGH-BCL 2易位分为两组。Bcl-2-/IGH-BCL 2-tFL的临床病理特征与传统FL不同，但其淋巴瘤发生机制尚不清楚。方法和结果采用免疫组化方法检测了7例Bcl-2-/IGH-BCL 2-tFL患者的表观遗传修饰基因EZH 2、MLL 2/KMT 2D、CBP/CREBBP、EP 300、H3 K27 me 3和H3 K4 me 3，Bcl-2-/IGH-BCL 2-tFL和Bcl-2阳性IGH-BCL 2易位阳性FL（Bcl-2+/IGH-BCL 2 +tFL）。大多数Bcl-2-/IGH-BCL 2-tFL保留了表观遗传修饰因子的阳性和H3 K27 me 3的低表达，尽管Bcl-2+/IGH-BCL 2 + tFL表现出EZH 2和CBP/CREBBP的异常免疫组化模式和H3 K27 me 3的过表达。使用靶向测序进一步分析了7例病例的样本，重点是409个关键肿瘤抑制基因和癌基因的外显子。Bcl-2-/IGH-BCL 2-tFL不存在文献报道的表观遗传修饰基因EZH 2、MLL 2/KMT 2D、MLL 3/KMT 2C、EP 300和ARID 1A的致病性突变，而Bcl-2+/IGH-BCL 2 + tFL可能是这些基因的致病性/致病性错义突变或移码突变。结论Bcl-2-/IGH-BCL 2-tFLs与Bcl-2+/IGH-BCL 2 +tFLs及其他FLs的发生可能存在不同的遗传和表观遗传异常。
AimsFollicular lymphoma (FL), comprising a minor subset of primary thyroid lymphomas, is divided into two groups based on Bcl‐2 expression andIGH‐BCL2translocation. The clinicopathological features exhibited by Bcl‐2‐negativeIGH‐BCL2translocation‐negative FL of the thyroid (Bcl‐2–/IGH‐BCL2–tFL) are different from those of conventional FL; however, its lymphomagenesis remains unclear. Here, we collected samples from seven patients with Bcl‐2–/IGH‐BCL2–tFL to investigate their epigenetic and genetic aberrations.Methods and resultsThe immunohistochemical profiles of epigenetic modifiers and the methylation status of histones were examined, including EZH2, MLL2/KMT2D, CBP/CREBBP, EP300, H3K27me3 and H3K4me3, in Bcl‐2–/IGH‐BCL2–tFL and Bcl‐2‐positiveIGH‐BCL2translocation‐positive FL of the thyroid (Bcl‐2+/IGH‐BCL2+tFL). Most Bcl‐2–/IGH‐BCL2–tFLs retained the positivity of epigenetic modifiers and lower expression of H3K27me3, although Bcl‐2+/IGH‐BCL2+tFLs exhibited aberrant immunohistochemical patterns of EZH2 and CBP/CREBBP and overexpression of H3K27me3. Samples from seven cases were further analysed using targeted sequencing, focusing on the exons of 409 key tumour suppressor genes and oncogenes. Bcl‐2–/IGH‐BCL2–tFLs do not have pathogenic mutations of epigenetic modifiers, such asEZH2,MLL2/KMT2D,MLL3/KMT2C,EP300andARID1A, which have been reported in FLs in the literature, whereas Bcl‐2+/IGH‐BCL2+tFLs are probably pathogenic/pathogenic missense mutations or frameshift mutations of these genes. Additionally, novel mutations inTET2andEP400were detected in Bcl‐2–/IGH‐BCL2–tFLs.ConclusionsDifferent genetic and epigenetic abnormalities might be involved in the oncogenesis of Bcl‐2–/IGH‐BCL2–tFLs from Bcl‐2+/IGH‐BCL2+tFLs and other FLs.
登录
查看更多内容
影响因子：
3.7
作者：
Chen, Cai;Bartenhagen, Christoph;Borkhardt, Arndt
通讯作者：
Borkhardt, Arndt
影响因子：
2
作者：
Hirokawa，Mitsuyoshi;Suzuki，Ayana;Kakudo，Kennichi
通讯作者：
Kakudo，Kennichi
DOI：
10.32388/afgal0
发表时间：
2020-02
期刊：
Definitions
影响因子：
--
作者：
通讯作者：
--
影响因子：
1.2
作者：
Noble，Victoria Vardell;Ermann，Daniel A.;Silberstein，Peter T.
通讯作者：
Silberstein，Peter T.
影响因子：
11.4
作者：
通讯作者：
--